Celleron Therapeutics Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding, Subsidiary
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
Phase 1
- Conditions
- Colorectal Neoplasms Malignant
- Interventions
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- Celleron Therapeutics Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT03993626
- Locations
- 🇬🇧
Celleron Therapeutics Ltd, Oxford, Oxfordshire, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath